Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
12. Dezember 2024 16:00 ET
|
Editas Medicine, Inc.
Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter...
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
09. Dezember 2024 12:00 ET
|
Editas Medicine, Inc.
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing...
Editas Medicine to Participate in Upcoming Investor Conferences
06. November 2024 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
04. November 2024 07:30 ET
|
Editas Medicine, Inc.
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel...
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
22. Oktober 2024 07:00 ET
|
Editas Medicine, Inc.
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a novel...
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
21. Oktober 2024 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant...
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
18. Oktober 2024 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar...
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
03. Oktober 2024 18:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other...
Editas Medicine to Participate in Upcoming Investor Conferences
28. August 2024 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
07. August 2024 07:00 ET
|
Editas Medicine, Inc.
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong...